Arcutis Biotherapeutics Inc (ARQT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $25.72 (-2.80%), Market cap $2.44B, 52-week low–high $13.04 ~ $31.20.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Financial statements, price targets, institutional (13F) holdings and related news for Arcutis Biotherapeutics Inc are updated in real time on BlackAll Trade.
Arcutis Biotherapeutics Inc trades at $25.72 (-2.80%). Real-time quotes and charts are available on BlackAll Trade.
Arcutis Biotherapeutics Inc has a market cap of about $2.44B.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilas